Anne Ducassou1, Emmanuelle Uro-Coste2, Pierre Verrelle3, Thomas Filleron4, Alexandra Benouaich-Amiel5, Vincent Lubrano6, Jean-Christophe Sol6, Marie-Bernadette Delisle2, Gilles Favre7, Solea Ken1, Anne Laprie8, Peter De Porre9, Christine Toulas10, Muriel Poublanc4, Elizabeth Cohen-Jonathan Moyal11. 1. Institut Claudius Regaud, Département de Radiothérapie, Toulouse F-31000, France. 2. CHU de Toulouse, Service d'Anatomie Pathologique, Hôpital de Rangueil, Toulouse F-31000, France; Université Paul Sabatier, Toulouse F-31000, France. 3. Centre Jean Perrin, Département de Radiothérapie, Clermont-Ferrand 63000, France. 4. Institut Claudius Regaud, Bureau des Etudes Cliniques, Toulouse F-31000, France. 5. Institut Claudius Regaud, Département d'Oncologie Médicale, Toulouse F-31000, France. 6. CHU de Toulouse, Service de Neurochirurgie, Hôpital de Rangueil, Toulouse F-31000, France; Université Paul Sabatier, Toulouse F-31000, France. 7. INSERM, Unité 1037, CRCT, Toulouse F-31000, France; Université Paul Sabatier, Toulouse F-31000, France. 8. Institut Claudius Regaud, Département de Radiothérapie, Toulouse F-31000, France; Université Paul Sabatier, Toulouse F-31000, France. 9. Janssen Research & Development, Turnhoutseweg 23, Beerse B-2340, Belgium. 10. INSERM, Unité 1037, CRCT, Toulouse F-31000, France. 11. Institut Claudius Regaud, Département de Radiothérapie, Toulouse F-31000, France; Université Paul Sabatier, Toulouse F-31000, France; INSERM, Unité 1037, CRCT, Toulouse F-31000, France. Electronic address: moyal.elizabeth@claudiusregaud.fr.
Abstract
BACKGROUND: Based on our previous results showing the involvement of the farnesylated form of RhoB in glioblastoma radioresistance, we designed a phase II trial associating the farnesyltransferase inhibitor Tipifarnib with radiotherapy in patients with glioblastoma and studied the prognostic values of the proteins which we have previously shown control this pathway. PATIENTS AND METHODS: Patients were treated with 200mg Tipifarnib (recommended dose (RD)) given continuously during radiotherapy. Twenty-seven patients were included in the phase II whose primary end-point was time to progression (TTP). Overall survival (OS) and biomarker analysis were secondary end-points. Expressions of αvβ3, αvβ5 integrins, FAK, ILK, fibroblast growth factor 2 (FGF2) and fibroblast growth factor receptor 1 (FGFR1) were studied by immuno-histochemistry in the tumour of the nine patients treated at the RD during the previously performed phase I and on those of the phase II patients. We evaluated the correlation of the expressions of these proteins with the clinical outcome. RESULTS: For the phase II patients median TTP was 23.1 weeks (95%CI = [15.4; 28.2]) while the median OS was 80.3 weeks (95%CI = [57.8; 102.7]). In the pooled phase I and II population, median OS was 60.4 w (95%CI = [47.3; 97.6]) while median TTP was 18.1 w (95%CI = [16.9; 25.6]). FGFR1 over-expression (HR = 4.65; 95%CI = [1.02; 21.21], p = 0.047) was correlated with shorter TTP while FGFR1 (HR = 4.1 (95% CI = [1.09-15.4]; p = 0.036)) and αvβ3 (HR = 10.38 (95%CI = [2.70; 39.87], p = 0.001)) over-expressions were associated with reduced OS. CONCLUSION: Association of 200mg Tipifarnib with radiotherapy shows promising OS but no increase in TTP compared to historical data. FGFR1 and αvβ3 integrin are independent bad prognostic factors of OS and TTP.
BACKGROUND: Based on our previous results showing the involvement of the farnesylated form of RhoB in glioblastoma radioresistance, we designed a phase II trial associating the farnesyltransferase inhibitor Tipifarnib with radiotherapy in patients with glioblastoma and studied the prognostic values of the proteins which we have previously shown control this pathway. PATIENTS AND METHODS: Patients were treated with 200mg Tipifarnib (recommended dose (RD)) given continuously during radiotherapy. Twenty-seven patients were included in the phase II whose primary end-point was time to progression (TTP). Overall survival (OS) and biomarker analysis were secondary end-points. Expressions of αvβ3, αvβ5 integrins, FAK, ILK, fibroblast growth factor 2 (FGF2) and fibroblast growth factor receptor 1 (FGFR1) were studied by immuno-histochemistry in the tumour of the nine patients treated at the RD during the previously performed phase I and on those of the phase II patients. We evaluated the correlation of the expressions of these proteins with the clinical outcome. RESULTS: For the phase II patients median TTP was 23.1 weeks (95%CI = [15.4; 28.2]) while the median OS was 80.3 weeks (95%CI = [57.8; 102.7]). In the pooled phase I and II population, median OS was 60.4 w (95%CI = [47.3; 97.6]) while median TTP was 18.1 w (95%CI = [16.9; 25.6]). FGFR1 over-expression (HR = 4.65; 95%CI = [1.02; 21.21], p = 0.047) was correlated with shorter TTP while FGFR1 (HR = 4.1 (95% CI = [1.09-15.4]; p = 0.036)) and αvβ3 (HR = 10.38 (95%CI = [2.70; 39.87], p = 0.001)) over-expressions were associated with reduced OS. CONCLUSION: Association of 200mg Tipifarnib with radiotherapy shows promising OS but no increase in TTP compared to historical data. FGFR1 and αvβ3 integrin are independent bad prognostic factors of OS and TTP.
Authors: Soléakhéna Ken; Alexandra Deviers; Thomas Filleron; Isabelle Catalaa; Jean-Albert Lotterie; Jonathan Khalifa; Vincent Lubrano; Isabelle Berry; Patrice Péran; Pierre Celsis; Elizabeth Cohen-Jonathan Moyal; Anne Laprie Journal: J Neurooncol Date: 2015-07-19 Impact factor: 4.130